Precision Targeting of the Gut Microbiome for Cancer Immunotherapy.

IF 29.7 1区医学 Q1 ONCOLOGY

Cancer discovery Pub Date : 2024-07-01 DOI:10.1158/2159-8290.CD-24-0538

Pasquale Lombardi, David J Pinato

引用次数: 0

Abstract

Transforming gut microbial status from a prognostic trait to a therapeutic target is a key goal to understand and reverse resistance to anticancer immunotherapy. Glitza and colleagues propose selective manipulation of the gut microbiome with SER401 following antibiotic preconditioning and highlight multiple challenges in delivering microbiome manipulation to the clinic. See related article by Glitza et al., p. 1161 (8).

查看原文本刊更多论文

精准靶向肠道微生物组，促进癌症免疫疗法。

将肠道微生物状态从预后特征转变为治疗靶点是了解和逆转抗癌免疫疗法耐药性的关键目标。Glitza 及其同事建议在抗生素预处理后用 SER401 选择性地操纵肠道微生物组，并强调了将微生物组操纵应用于临床的多重挑战。请参阅 Glitza 等人的相关文章，第 1161 页（8）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.